Ergoteles’s Tvardi Therapeutics TVRD Stock Holding History

Ergoteles’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-9,952	Closed	-$1.01M	–	893
2023 Q2	$1.01M	Buy	+9,952	New	+$1.37M	0.05%	459

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

Ergoteles's TVRD Position: Q3 2023 in Review

Ergoteles sold out of Tvardi Therapeutics (TVRD) in Q3 2023, closing a stake of 9,952 shares — an estimated $1.01M sold.

Ergoteles first reported a position in TVRD in Q2 2023 and held it in 1 quarter. The position peaked at $1.01M in Q2 2023. 121 funds tracked by Wall St. Rank hold TVRD as of Q3 2023.

Ergoteles reported no remaining Tvardi Therapeutics position as of Q3 2023 after selling out during the quarter.
Ergoteles sold 9,952 Tvardi Therapeutics shares in Q3 2023, an estimated $1.01M.
Ergoteles first reported a position in Tvardi Therapeutics in Q2 2023 and held it in 1 quarter.
Ergoteles's Tvardi Therapeutics position peaked at $1.01M in Q2 2023.
121 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.